Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.

Kasagga, Alousious et al.·Cureus·2025·
RPEP-117372025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.
Published In:
Cureus, 17(8), e90335 (2025)
Database ID:
RPEP-11737

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-11737·https://rethinkpeptides.com/research/RPEP-11737

APA

Kasagga, Alousious; Rebellow, Delvy; Hashmi, Tooba; Husami, Malik Y; Lama, Pooja; Arul Selvan, Kaavya; Nakasagga, Kevin. (2025). Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.. Cureus, 17(8), e90335. https://doi.org/10.7759/cureus.90335

MLA

Kasagga, Alousious, et al. "Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.." Cureus, 2025. https://doi.org/10.7759/cureus.90335

RethinkPeptides

RethinkPeptides Research Database. "Comparative Efficacy and Tolerability of Tirzepatide Versus ..." RPEP-11737. Retrieved from https://rethinkpeptides.com/research/kasagga-2025-comparative-efficacy-and-tolerability

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.